Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Management of Immune-Related Adverse Events Affecting Outcome in Patients Treated With Checkpoint Inhibitors

Management of Immune-Related Adverse Events Affecting Outcome in Patients Treated With Checkpoint... Letters caution. Indeed, subgroup analyses in clinical trials offer value involved axillary lymph nodes showed a 14.6% absolute dif- as hypothesis generation for further research. ference in 20-year overall survival. We agree that this sub- In addition, patients with ERBB2-overexpressing/ group result needs validation in a prospective trial using con- amplified disease represented a significant portion of the study temporary chemotherapy regimens in the control arm. The population (21% of the HDCT group; 24% of the conventional- SUBITO trial (NCT02810743) has been designed with this aim dose chemotherapy group), and in the subgroup analysis of and is currently open for enrollment. Based on our improved patients with 10 or more involved lymph nodes, 25.3% (40 of understanding of disease biology, the SUBITO trial includes 158) were characterized as ERBB2-overexpressing/amplified. patients with stage III, ERBB2-negative breast cancer with a Since the 1990s treatment era in which the study originated, BRCA1-like phenotype. fundamental advances in systemic therapies have transformed Several studies have reported an increased risk of develop- survival outcomes with the standard utilization of ERBB2- ing cardiovascular disease after chemotherapy and radio- 3 3 targeted agents, rendering conclusions from these data chal- therapy for early breast cancer. Early detection and http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Oncology American Medical Association

Management of Immune-Related Adverse Events Affecting Outcome in Patients Treated With Checkpoint Inhibitors

Loading next page...
 
/lp/american-medical-association/management-of-immune-related-adverse-events-affecting-outcome-in-r2u1Wq10mz
Publisher
American Medical Association
Copyright
Copyright 2020 American Medical Association. All Rights Reserved.
ISSN
2374-2437
eISSN
2374-2445
DOI
10.1001/jamaoncol.2020.1932
Publisher site
See Article on Publisher Site

Abstract

Letters caution. Indeed, subgroup analyses in clinical trials offer value involved axillary lymph nodes showed a 14.6% absolute dif- as hypothesis generation for further research. ference in 20-year overall survival. We agree that this sub- In addition, patients with ERBB2-overexpressing/ group result needs validation in a prospective trial using con- amplified disease represented a significant portion of the study temporary chemotherapy regimens in the control arm. The population (21% of the HDCT group; 24% of the conventional- SUBITO trial (NCT02810743) has been designed with this aim dose chemotherapy group), and in the subgroup analysis of and is currently open for enrollment. Based on our improved patients with 10 or more involved lymph nodes, 25.3% (40 of understanding of disease biology, the SUBITO trial includes 158) were characterized as ERBB2-overexpressing/amplified. patients with stage III, ERBB2-negative breast cancer with a Since the 1990s treatment era in which the study originated, BRCA1-like phenotype. fundamental advances in systemic therapies have transformed Several studies have reported an increased risk of develop- survival outcomes with the standard utilization of ERBB2- ing cardiovascular disease after chemotherapy and radio- 3 3 targeted agents, rendering conclusions from these data chal- therapy for early breast cancer. Early detection and

Journal

JAMA OncologyAmerican Medical Association

Published: Aug 18, 2020

References